Apotex Corp.

Court rules in favor of Canadian drug maker in gabapentin ruling

Published in Law and Health Weekly, October 1st, 2005

Apotex Corp. announced that the U.S. District Court for the District of New Jersey granted Apotex's motion for summary judgment of noninfringement, finding that Apotex's gabapentin capsule formulation does not infringe Pfizer's U.S. Patent no. 6,054,482 for Neurontin.

"We are very pleased with this decision," said Apotex CEO Dr. Barry Sherman. "This confirms what we believed all along: Our generic version of Neurontin does not infringe Pfizer's patent and deserves to be on the market," Sherman commented.

Gabapentin is the generic name for Neurontin, approved to treat seizures and postherapeutic neuralgia and marketed by Warner-Lambert, a unit of...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Law and Health Weekly

Source: Law and Health Weekly (2005-10-01)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry